Deucravacitinib (Sotyktu) for psoriasis

Deucravacitinib (brand name Sotyktu) is an oral medicine taken as a pill once a day, not an injection or infusion like most biologics. It is a tyrosine kinase 2 (TYK2) inhibitor, but it works differently from the JAK1/JAK2/JAK3 inhibitors used elsewhere in vitiligo and psoriasis care. It binds a regulatory part of the TYK2 enzyme rather than its active site, an approach called allosteric inhibition. That binding lowers signaling from several inflammatory pathways involved in psoriasis, including interleukin-23, interleukin-12, and type I interferon. The exact reason it works better for some people than others is not established.⌁ Evidence⌁ Evidence

The current label approves deucravacitinib for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is separately approved for active psoriatic arthritis in adults. The label advises against combining it with other potent immunosuppressants, and against live vaccines while on treatment. It should not be started during an active or serious infection, including active tuberculosis or hepatitis B or C, and calls for a tuberculosis check before starting. Unlike apremilast’s label, it does not name phototherapy or topical treatments as things it can be combined with. It lists phototherapy as an alternative for the same eligible patients, not a documented combination partner.⌁ Evidence

People I have heard from ask what to do when the treatment they are on stops working. Deucravacitinib is one 6 mg tablet by mouth once a day, with or without food, at the full dose from day one. There is no step-up titration schedule like apremilast’s, and the tablet should not be crushed, cut, or chewed. In the label’s own phase 3 trials (POETYK PSO-1 and PSO-2), 58% and 53% of people taking deucravacitinib reached 75% or greater clearing (PASI 75) by week 16. Placebo reached 13% and 9%, and an apremilast comparator arm in the same trials reached 35% and 40%. By week 24, deucravacitinib’s PASI 75 rate rose to 69% (PSO-1) and 58% (PSO-2), versus 38% on apremilast in both trials.⌁ Evidence

Deucravacitinib carries no boxed warning, but it does carry real warnings worth knowing. It can increase the risk of infections, including serious ones; the label advises against starting it during an active or serious infection. Herpes zoster (shingles) has been reported, including a multidermatomal form in some people with a normally functioning immune system. A small number of lymphoma cases were reported in trials (0.3 per 100 patient-years). It commonly raises a muscle enzyme called creatine phosphokinase (CPK), and the label says to discontinue if it rises markedly. Triglycerides are checked periodically. Liver enzymes are checked at baseline and during treatment only if you have known or suspected liver disease, unlike the routine bloodwork methotrexate or cyclosporine require for everyone. In the week-16 psoriasis trials, the most common reactions were upper respiratory infections (19.2% versus 14.8% on placebo) and CPK increase (2.7% versus 1.2%). Less common reactions were herpes simplex (2.0% versus 0.2%), mouth ulcers (1.9% versus 0%), folliculitis (1.7% versus 0%), and acne (1.4% versus 0.2%).⌁ Evidence

Sotyktu has no generic version. Independent price snapshots put the average retail cash price for 30 tablets of Sotyktu 6 mg at roughly $6,978, with a GoodRx-coupon price around $6,832. Bristol Myers Squibb’s own SOTYKTU 360 Support Co-Pay Program states eligible patients with commercial insurance may pay as little as $0 for a 30-day supply. Monthly, annual, or per-claim maximums can apply. The program’s own terms exclude anyone with Medicare, Medicaid, Medigap, TRICARE, VA, or another government-funded plan. Uninsured or underinsured patients facing financial hardship can instead be referred to the separate, independent Bristol Myers Squibb Patient Assistance Foundation for free medicine.⌁ Evidence⌁ Evidence

No reader has sent me a first-hand account of deucravacitinib for psoriasis yet. Until someone does, here is what the label and the studies say about living with it.⌁ Evidence

Since there is no titration step to log, track how you feel day to day from the start instead. Note any signs of infection, such as fever, unusual fatigue, or a cough, and report them promptly, since the label flags an increased infection risk. Watch for a rash that follows a band on one side of the body, a possible sign of shingles, even without a prior history of it. If you have known liver disease, keep any scheduled liver-enzyme test appointments. Add a same-conditions photo around the sixteen-week mark, matching the trial timeline the PASI 75 results describe.⌁ Evidence